Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 20 Debt-to-Equity is 0.11 as of Jun. 2026, which is at its 10-year median of 0.11. GuruFocus rates ASX:S66 with a GF Score™ of 20/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,764 Consumer Packaged Goods companies, Star Combo Pharma ranks better than 78.4% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Star Combo Pharma's Debt-to-Equity or its related term are showing as below:
ASX:S66'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.11 Max: 0.16
Current: 0.11
During the past 10 years, the highest Debt-to-Equity Ratio of Star Combo Pharma was 0.16. The lowest was 0.00. And the median was 0.11.
ASX:S66's Debt-to-Equity is ranked better than 78.4% of 1764
companies
in the Consumer Packaged Goods industry
Industry Median: 0.41
vs ASX:S66: 0.11
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Star Combo Pharma Debt-to-Equity Related Terms
Star Combo Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Star Combo Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Star Combo Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Combo Pharma (ASX:S66) has a Debt-to-Equity of 0.11 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Star Combo Pharma and its competitors. This is near median its historical median of 0.11. According to the industry distribution chart, Star Combo Pharma ranks #381 out of 1764 companies in the Consumer Packaged Goods industry, placing it in the top 21.6%.
Is Star Combo Pharma's Debt-to-Equity too high?
Star Combo Pharma's current Debt-to-Equity of 0.11 is near median its 10-year median of 0.11. The Consumer Packaged Goods industry median Debt-to-Equity is 0.41. Star Combo Pharma's value of 0.11 is 73.2% below this industry median. Based on the distribution chart, Star Combo Pharma ranks #381 out of 1764 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Star Combo Pharma has a GF Score™ of 20/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's Debt-to-Equity compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #381 out of 1764 companies for Debt-to-Equity. This places Star Combo Pharma in the top 22% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.41. Star Combo Pharma's value of 0.11 is 73.2% below this benchmark. While the company's 10-year median is 0.11 vs. the industry median of 0.41, Star Combo Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.41, based on 1,764 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current Debt-to-Equity of 0.11 is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Star Combo Pharma and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current Debt-to-Equity is 0.11, which is near median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.14 — trading 7.7% above its estimated fair value. The current Debt-to-Equity is 0.11, which is near median its 10-year median of 0.11 and 73.2% below the Consumer Packaged Goods industry median of 0.41. Star Combo Pharma's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current Debt-to-Equity is 0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be overvalued.
The current stock price of A$0.14 is trading 7.7% above its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
Debt-to-Equity: 0.11 (near median its 10-year median of 0.11)
GF Value™: A$0.13 vs. price of A$0.14 (7.7% above fair value)
Industry Position: 73.2% below the Consumer Packaged Goods median (#381 of 1764)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
20GF Score
Get the complete analysis for ASX:S66
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
